RVRC Revium Rx.
Pharmaceutical Preparations · OTC · SEC CIK 1839140 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets22.4%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $443,000 | $473,000 | $391,000 | $218,000 |
| SG&A expense | $289,000 | $266,000 | $547,000 | $519,000 |
| Operating income | -$732,000 | -$739,000 | -$938,000 | -$737,000 |
| Net income | -$748,000 | -$725,000 | -$1.04M | -$634,000 |
| EBITDA | -$732,000 | -$737,000 | — | — |
| EPS (basic) | 0.01 | 0.01 | 0.02 | 0.01 |
| EPS (diluted) | 0.01 | 0.01 | 0.02 | 0.01 |
| Weighted avg. shares (diluted) | 60.73M | 60.73M | 60.73M | 60.73M |
| Balance sheet | ||||
| Cash & equivalents | $842,000 | $920,000 | $3.65M | $3.91M |
| Current assets | $1.86M | $2.48M | — | — |
| PP&E, net | $9,000 | $9,000 | — | — |
| Goodwill | $2.58M | $2.58M | — | — |
| Intangibles | $2.50M | $2.50M | — | — |
| Total assets | $7.11M | $7.75M | — | — |
| Current liabilities | $971,000 | $1.53M | — | — |
| Total liabilities | $1.59M | $1.60M | — | — |
| Shareholders' equity | $5.52M | $6.16M | $18.53M | $19.41M |
| Shares outstanding | 60.73M | 60.73M | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$626,000 | -$541,000 | -$759,000 | -$357,000 |
| Investing cash flow | $548,000 | -$217,000 | $496,000 | $1.00M |
| Depreciation & amortization | $0 | $2,000 | — | — |
| Stock-based compensation | $111,000 | — | $154,000 | $340,000 |
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.